Ingredion
INGR
94.25
-2.50
-2.58%
Ingredion
US · INGR
#1925 by market cap
Listed 1970
94.25
-2.50
-2.58%
Live - 5344 symbols - heartbeat 98s ago
· 2026-10-07 19:54
After-hours
94.25
0.00%
- Market cap
- 5.94B
- P/E (TTM)i
- 10.24
- P/Bi
- 1.31
- EPSi
- 11.18
- Div yieldi
- 3.48%
- 52W posi
- 5%
Reader sentiment
Are you bullish or bearish on INGR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.68, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.84% YoY
Margins
- Gross margin
- 25.32%
- Operating margin
- 14.36%
- Net margin
- 10.10%
Key ratios & quality
- Enterprise valuei
- 6.76B
- PEG ratioi
- 0.73
- Altman Z-Scorei
- 3.68
PEG uses trailing P/E against the 3-year net income growth rate (14.00%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.29B | 6.21B | 5.99B | 6.89B | 7.95B | 8.16B | 7.43B | 7.22B |
| Gross profit | 1.37B | 1.31B | 1.27B | 1.33B | 1.49B | 1.75B | 1.79B | 1.83B |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 767.00M | 721.00M | 675.00M | 697.00M | 766.00M | 968.00M | 1.01B | 1.04B |
| Pretax profit | 621.00M | 582.00M | 506.00M | 248.00M | 668.00M | 839.00M | 931.00M | 974.00M |
| Tax | 167.00M | 158.00M | 152.00M | 123.00M | 166.00M | 188.00M | 277.00M | 238.00M |
| Net profit | 454.00M | 424.00M | 354.00M | 125.00M | 502.00M | 651.00M | 654.00M | 736.00M |
| Basic EPS | 6 | 6 | 5 | 2 | 7 | 10 | 10 | 11 |
| Diluted EPS | 6.17 | 6.13 | 5.15 | 1.73 | 7.34 | 9.60 | 9.71 | 11.18 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.81B | 1.83B | 1.82B | 1.76B | 1.79B | 1.85B |
| Gross profit | 466.00M | 477.00M | 455.00M | 430.00M | 401.00M | 426.00M |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 283.00M | 274.00M | 252.00M | 228.00M | 214.00M | 233.00M |
| Pretax profit | 267.00M | 259.00M | 241.00M | 207.00M | 194.00M | 175.00M |
| Tax | 68.00M | 61.00M | 69.00M | 40.00M | 50.00M | 59.00M |
| Net profit | 199.00M | 198.00M | 172.00M | 167.00M | 144.00M | 116.00M |
| Basic EPS | 3 | 3 | 3 | 3 | 2 | 2 |
| Diluted EPS | 3.00 | 2.99 | 2.61 | 2.56 | 2.22 | 1.78 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.14B | 2.16B | 2.65B | 2.70B | 3.31B | 3.40B | 3.36B | 3.51B |
| Cash & ST investments | 334.00M | 268.00M | 665.00M | 332.00M | 239.00M | 409.00M | 1.01B | 1.03B |
| Inventory | 824.00M | 861.00M | 917.00M | 1.17B | 1.60B | 1.45B | 1.19B | 1.23B |
| Total assets | 5.73B | 6.04B | 6.86B | 7.00B | 7.56B | 7.64B | 7.44B | 7.90B |
| Total current liabilities | 946.00M | 967.00M | 1.46B | 1.51B | 1.88B | 1.77B | 1.28B | 1.32B |
| Short-term debt | 169.00M | 123.00M | 484.00M | 355.00M | 591.00M | 504.00M | 103.00M | 111.00M |
| Long-term debt | 1.93B | 1.77B | 1.75B | 1.74B | 1.94B | 1.74B | 1.79B | 1.74B |
| Total liabilities | 3,320,000,000.00 | 3,268,000,000.00 | 3,786,000,000.00 | 3,774,000,000.00 | 4,299,000,000.00 | 3,992,000,000.00 | 3,554,000,000.00 | 3,531,000,000.00 |
| Total equity | 2.41B | 2.77B | 3.07B | 3.23B | 3.26B | 3.65B | 3.89B | 4.37B |
| Retained earnings | 3.54B | 3.78B | 3.96B | 3.90B | 4.21B | 4.65B | 5.09B | 5.61B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.37B | 3.52B | 3.52B | 3.51B | 3.53B | 3.52B |
| Cash & ST investments | 846.00M | 868.00M | 921.00M | 1.03B | 918.00M | 952.00M |
| Inventory | 1.17B | 1.22B | 1.23B | 1.23B | 1.18B | 1.11B |
| Total assets | 7.47B | 7.78B | 7.83B | 7.90B | 7.93B | 8.07B |
| Total current liabilities | 1.18B | 1.26B | 1.28B | 1.32B | 1.28B | 1.26B |
| Short-term debt | 42.00M | 46.00M | 57.00M | 111.00M | 83.00M | 41.00M |
| Long-term debt | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B |
| Total liabilities | 3,420,000,000.00 | 3,505,000,000.00 | 3,509,000,000.00 | 3,531,000,000.00 | 3,482,000,000.00 | 3,497,000,000.00 |
| Total equity | 4.05B | 4.28B | 4.32B | 4.37B | 4.45B | 4.57B |
| Retained earnings | 5.24B | 5.38B | 5.50B | 5.61B | 5.70B | 5.76B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 703.00M | 680.00M | 829.00M | 392.00M | 152.00M | 1.06B | 1.44B | 944.00M |
| Depreciation & amortization | 247.00M | 220.00M | 213.00M | 220.00M | 215.00M | 219.00M | 214.00M | 222.00M |
| Free cash flow | 353.00M | 352.00M | 489.00M | 92.00M | -148.00M | 743.00M | 1.14B | 511.00M |
| Dividends paid | -182.00M | -174.00M | -178.00M | -184.00M | -181.00M | -194.00M | -210.00M | -211.00M |
| Stock buybacks / issuance | -657.00M | 66.00M | 4.00M | -68.00M | -112.00M | -101.00M | -216.00M | -224.00M |
| Ending cash balance | 327.00M | 264.00M | 665.00M | 328.00M | 236.00M | 401.00M | 997.00M | 1.03B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 77.00M | 185.00M | 277.00M | 405.00M | 33.00M | 90.00M |
| Depreciation & amortization | 55.00M | 53.00M | 57.00M | 57.00M | 55.00M | 55.00M |
| Free cash flow | -15.00M | 84.00M | 172.00M | 270.00M | -77.00M | -10.00M |
| Dividends paid | -52.00M | -54.00M | -51.00M | -54.00M | -52.00M | -53.00M |
| Stock buybacks / issuance | -55.00M | 0 | -79.00M | -90.00M | -14.00M | 0 |
| Ending cash balance | 837.00M | 861.00M | 915.00M | 1.03B | 914.00M | 948.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 16.78 | 16.17 | 12.21 | 3.83 | 15.54 | 18.95 | 17.35 | 17.78 |
| ROA %i | 7.50 | 7.02 | 5.40 | 1.69 | 6.76 | 8.46 | 8.58 | 9.50 |
| ROIC %i | 10.72 | 10.18 | 7.77 | 3.19 | 10.06 | 12.33 | 11.34 | 12.40 |
| 5-year avg ROE %i | 18.10 | 18.22 | 16.92 | 13.57 | 12.87 | 13.31 | 13.56 | 14.69 |
| EBIT margin %i | 11.16 | 10.73 | 9.59 | 4.67 | 9.65 | 11.68 | 13.06 | 14.00 |
| FCF / sales %i | 5.61 | 5.67 | 8.17 | 1.33 | -- | 9.08 | 15.28 | 7.08 |
| Current ratioi | 2.26 | 2.23 | 1.82 | 1.78 | 1.76 | 1.92 | 2.62 | 2.66 |
| Quick ratioi | 1.36 | 1.29 | 1.15 | 0.97 | 0.88 | 0.95 | 1.64 | 1.69 |
| Debt / assetsi | 36.68 | 33.25 | 34.53 | 32.10 | 35.41 | 31.42 | 27.34 | 24.96 |
| LT debt / equityi | 80.90 | 68.52 | 63.20 | 60.33 | 65.29 | 52.80 | 50.00 | 42.88 |
| Interest coveragei | 8.67 | 7.93 | 8.44 | 4.35 | 7.75 | 8.36 | 24.87 | 27.32 |
| Revenue CAGR (3Y) %i | 1.82 | 0.69 | -1.39 | 3.11 | 8.57 | 10.87 | 2.53 | -3.15 |
| Net income CAGR (3Y) %i | 3.29 | -5.22 | -12.47 | -35.84 | 6.01 | 22.71 | 76.84 | 14.00 |
| FCF CAGR (3Y) %i | -4.56 | -10.26 | 2.43 | -36.12 | -- | 14.96 | 131.47 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 16.13 | 16.89 | 15.88 | 17.78 | 15.97 | 13.42 |
| ROA %i | 8.49 | 9.01 | 8.58 | 9.50 | 8.76 | 7.47 |
| ROIC %i | 11.32 | 12.00 | 11.49 | 12.40 | 11.65 | 10.50 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 12.92 | 13.42 | 13.16 | 14.00 | 13.03 | 12.43 |
| FCF / sales %i | 13.26 | 10.98 | 7.52 | 7.08 | 6.24 | 4.92 |
| Current ratioi | 2.85 | 2.78 | 2.75 | 2.66 | 2.76 | 2.80 |
| Quick ratioi | 1.80 | 1.76 | 1.75 | 1.69 | 1.78 | 1.86 |
| Debt / assetsi | 23.89 | 22.97 | 22.95 | 24.96 | 23.02 | 22.09 |
| LT debt / equityi | 43.34 | 40.98 | 40.53 | 42.88 | 39.38 | 38.09 |
| Interest coveragei | 32.79 | 31.68 | 25.84 | 27.32 | 25.35 | 11.21 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Texture & Healthful Solutions (T&HS) is the largest reported line at 35.78% of revenue, across 5 reported segments.
- No single line clears half of revenue; Food & Industrial Ingredients (F&II) - Latin America (LATAM) is next at 33.62%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Texture & Healthful Solutions (T&HS)35.78%
Food & Industrial Ingredients (F&II) - Latin America (LATAM)33.62%
Food & Industrial Ingredients (F&II)- United States(U.S.) /Canada28.97%
All other7.14%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.